Other comprehensive income (loss) attributable to Bio-Techne (6,925) 14,057: Comprehensive income attributable to Bio-Techne: $ 62,690: $ 47,452: Earnings per share attributable to Bio-Techne: Basic (in dollars per share) $ 1.78: $ 0.87: Diluted (in dollars per share) $ 1.69: $ 0.83: Weighted average common shares outstanding: Basic (in shares ...
Show more
See More
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the …
Show more
See More
Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of …
Show more
See More
The annual dividend yield may reach 0.29%. Bio-Techne reported GAAP net income of $68.981 million for 3M 2022, up 2.1 times from $33.395 million in the previous year. Revenues increased 26.2% to $257.719 million from $204.199 million a year earlier. The Bio-Techne Board of Directors announced a quarterly dividend of $0.32 per share.
See More
From the customer seal specification sheet When the customer has a clear idea to what profile he needs, Techné will then provide its expertise. A complete revision of the required specifications (environment, dynamic/static, temperature, pressure, standards and certifications, etc.)
Show more
See More
Chuck Kummeth became President and Chief Executive Officer of Bio-Techne Corporation on April 1, 2013. Prior to joining the Company, he served as President of Mass Spectrometry and Chromatography at Thermo Fisher Scientific Inc. and was President of that company’s Laboratory Consumables Division from 2009 to September 2011.
Show more
See More
Connecticut. 2 Barnes Industrial Road South Wallingford, CT 06492 USA Tel: (203) 679-0395 Fax: (203) 679-0452
Show more
See More
Show more
See More
Aug 10, 2019 . Techne Infra India Private Limited is a Private incorporated on 14 December 2010. It is classified as Non-govt company and is registered at Registrar of Companies, Mumbai. Its authorized share capital is Rs. 10,000,000 and its paid up capital is Rs. 5,035,800.
Show more
See More
We think Bio-Techne is no more beholden to its lenders, than the birds are to birdwatchers. To our minds it has a healthy happy balance sheet. When analysing debt levels, the balance sheet is the obvious place to start. However, not all investment risk resides within the balance sheet - far from it.
Show more
See More
Tecal 140F. The Tecal 140F is part of a new range of light-weight and portable field Dri-Block calibrators. This model operates from 45°C below ambient (typically -20°C) up to 140°C. All Tecal 140F models are offered with RS-232 communications and can be used with a …
Show more
See More
Two different processes exist : with a cutting blade or with a punch press. The material comes either in rolls or in sheets and is placed on the cutting table. The press is equipped with a cutting tool made specifically according to the wished 2D profile. The piston moves down and the tool separates the parts from the rubber sheet. This process ...
Show more
See More
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the …
Show more
See More
1 day ago . Precisely like the name suggests, Techne is an exposé of craft, one man testing his own aptitude. “How far can I push my abilities, and what direction can I push them into?” Weiss asks ...
Show more
See More
Michael Deines joined Bio-Techne in May 2020 as Vice President, Reagent Solutions Division bringing over 30 years of Life Science industry leadership experience to his role. Prior to joining Bio-Techne, he served as General Manager, Environmental and Analytical Reagents.
Steve Crouse joined Bio-Techne in March 2021 as the Vice President, Analytical Solutions Development, responsible for Bio-Techne’s ProteinSimple branded products and R&D Systems Immunoassays portfolio. Steve has >20 years of experience leading R&D, Business Development, Marketing and Sales organizations.
Mr. Silverman holds a Bachelor of Science degree from the University of Vermont and attended the Advanced Management Program at INSEAD. Kevin Smyth joined Bio-Techne on January 8, 2018 as the Chief Digital Officer.